There are currently no expansion plans for the Active Pharmaceutical Ingredient Business. CSPC Innovation Pharmaceutical is expected to receive the first installment of the BD payment in the first half of this year | Focus on the Earnings Conference.
① In the future, CSPC Innovation Pharmaceutical will continue to explore SYS6010 (EGFR ADC) for indications such as gastrointestinal cancer. ② CSPC Innovation Pharmaceutical has reviewed the progress of its GLP-1 products, stating that some MNCs have already expressed interest in the company's related varieties. ③ The Active Pharmaceutical Ingredient business is currently focused on cost reduction through process technology upgrades, with no plans for expansion at this time.
The training tool for Siasun Robot&Automation is here! The embodied intelligence simulation platform "Ge Wu" is officially released.
① It is reported that "Ge Wu" integrates advanced reinforcement learning frameworks and multimodal motion control technology. ② Professor Ye Linqi, an open-source contributor to the "Ge Wu" platform, believes that future embodied intelligence needs to meet the most basic survival needs. ③ Brokerage firms believe that the second half of 2025 will be a stage for the rapid advancement of humanoid robot commercialization.
Germany increases fiscal spending to promote Energy transition, and China’s solar storage sector welcomes new investment opportunities abroad.
Recently, the German Federal Parliament passed a spending bill worth 500 billion euros with more than two-thirds of the votes. The bill proposes that 100 billion euros be injected into the existing climate and transformation Fund to support the Energy transition and climate protection. The Soochow securities electric new team pointed out that as Germany increases financial support for Energy transition development, the installed capacity of photovoltaic and energy storage is expected to accelerate growth at a turning point, and the demand for Power Inverter exports is expected to benefit.
"Burned" over 0.8 billion yuan in R&D expenses, CSPC Innovation Pharmaceutical experiences a decline in revenue and net profit | Interpretations
① The functional foods and ingredients business segment experienced a decrease in main business revenue while research and development expenses significantly increased, resulting in declines in revenue and Net income for CSPC Innovation Pharmaceutical in 2024. ② In 2024, the company achieved certain results in the field of Innovative Drugs.
Midea's entry into humanoid robots, UBS Group: Not surprising, Midea can leverage supply chain resources.
UBS Group believes that by 2035, the market size for humanoid robots in China is expected to reach 200-300 billion yuan. Domestic companies place greater emphasis on Hardware and system integration capabilities. Although there is limited profit contribution in the short term, due to the increasing market attention on the white goods Industry and AI/Siasun Robot&Automation themes, the stock price of Midea may continue to rise in the short term.
After a continuous reduction in market trading volume, a short-term directional choice may be faced, waiting for new hotspots to break through.
Yesterday, the market continued a low-volume consolidation structure. From the Index perspective, although it is still in a relatively strong consolidation structure, the narrow fluctuations over the past three days may indicate that the market is facing a new round of directional choices. If it cannot attack with increased volume again, the probability of subsequent corrective consolidation may further increase.